(Q37821495)

23 August 2017

1 reference

title

Acute infusion reactions induced by monoclonal antibody therapy (English)

1 reference

23 August 2017

1 reference

1 reference

Enrico Maggi

1

1 reference

PubMed ID

21162650

23 August 2017

Alessandra Vultaggio

series ordinal

2

1 reference

PubMed ID

21162650

23 August 2017

Andrea Matucci

series ordinal

3

1 reference

23 August 2017

1 January 2011

1 reference

Expert Review of Clinical Immunology

23 August 2017

1 reference

23 August 2017

7

1 reference

23 August 2017

1

1 reference

23 August 2017

55-63

1 reference

The Nature of Adverse Events in Hospitalized Patients

23 August 2017

1 reference

Adverse side-effects to biological agents

21 January 2018

1 reference

Does safety make a difference in selecting the right TNF antagonist?

21 January 2018

1 reference

The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients

21 January 2018

1 reference

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

21 January 2018

1 reference

Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia

21 January 2018

1 reference

EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer

21 January 2018

1 reference

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

21 January 2018

1 reference

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy

21 January 2018

1 reference

Natalizumab for multiple sclerosis

21 January 2018

1 reference

The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL.

21 January 2018

1 reference

American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis

21 January 2018

1 reference

Engineering of therapeutic antibodies to minimize immunogenicity and optimize function

21 January 2018

1 reference

The safety and side effects of monoclonal antibodies

21 January 2018

1 reference

Natalizumab Induction and Maintenance Therapy for Crohn's Disease

21 January 2018

1 reference

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

21 January 2018

1 reference

Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles

21 January 2018

1 reference

An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status

21 January 2018

1 reference

Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease

21 January 2018

1 reference

Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions.

21 January 2018

1 reference

Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma

21 January 2018

1 reference

Effect of aerosolized anti-IgE (E25) on airway responses to inhaled allergen in asthmatic subjects

21 January 2018

1 reference

The biology of IGE and the basis of allergic disease

21 January 2018

1 reference

5. IgE, mast cells, basophils, and eosinophils

21 January 2018

1 reference

Management and preparedness for infusion and hypersensitivity reactions

21 January 2018

1 reference

Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose

21 January 2018

1 reference

Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment.

21 January 2018

1 reference

Hypersensitivity reactions to the polysorbate contained in recombinant erythropoietin and darbepoietin

21 January 2018

1 reference

Severe anaphylactic reaction during the second infusion of infliximab in a patient with psoriatic arthritis

21 January 2018

1 reference

Severe adverse reactions to Infliximab therapy are common in young children with inflammatory bowel disease.

21 January 2018

1 reference

Fatal and Near-Fatal Anaphylactic Reactions to Food in Children and Adolescents

21 January 2018

1 reference

Anaphylaxis: lessons from mouse models

21 January 2018

1 reference

Platelet-activating factor, PAF acetylhydrolase, and severe anaphylaxis

21 January 2018

1 reference

Infusion reactions: diagnosis, assessment, and management

21 January 2018

1 reference

B cells as a therapeutic target in autoimmune diseases other than rheumatoid arthritis

21 January 2018

1 reference

Safety of rituximab in the treatment of B cell malignancies: implications for rheumatoid arthritis

21 January 2018

1 reference

Cytokine-release syndrome: overview and nursing implications

21 January 2018

1 reference

Tolerability and safety of rituximab (MabThera).

21 January 2018

1 reference

The impact of infliximab infusion reactions on long-term outcomes in patients with Crohn's disease

21 January 2018

1 reference

Infliximab in the treatment of Crohn's disease: a user's guide for clinicians

21 January 2018

1 reference

Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial

21 January 2018

1 reference

Review and expert opinion on prevention and treatment of infliximab-related infusion reactions

21 January 2018

1 reference

Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis.

21 January 2018

1 reference

Infliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction

21 January 2018

1 reference

Infliximab maintenance therapy for fistulizing Crohn's disease

21 January 2018

1 reference

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial

21 January 2018

1 reference

Review article: Infliximab therapy for inflammatory bowel disease--seven years on

21 January 2018

1 reference

Infliximab reintroduction is not associated to a higher rate of immune-related adverse effects in patients with inflammatory bowel disease initially treated with a three-infusion induction regimen.

21 January 2018

1 reference

Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer

21 January 2018

1 reference

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

21 January 2018

1 reference

Biological agents: new drugs, old problems.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ECI.10.90

1 reference

23 August 2017

1 reference

PubMed ID

21162650